Skip to content

FIND Stroke Recovery - A Longitudinal Study

FIND Stroke Recovery: A Longitudinal Frequent Evaluation Long-term Follow-up Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05708807
Acronym
FIND
Enrollment
600
Registered
2023-02-01
Start date
2018-02-01
Completion date
2030-12-31
Last updated
2025-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Impairment, Risk Factor, Cardiovascular, Stroke, Stroke Hemorrhagic, Stroke, Ischemic

Keywords

recovery, rehabilitation, stroke severity, plasticity, modified Rankin Scale, National Institutes of Health Stroke Scale, Fugl-Meyer assessment, blood sampling, stroke subtype

Brief summary

Stroke survivors frequently suffer disabilities including motor and cognitive problems, impairments in speech and vision, depression, and several other disabilities that worsen their quality of life. Some will recover fully after stroke and others will have permanent impairments. Few studies show trajectories of recovery in different domains after stroke, hence recovery time-lines are not fully known. Also, the whole range of mechanisms leading to recovery are not precisely known (1). To monitor those mechanisms one can utilize biomarkers. In parallel to the studies of recovery, studies on time series of biomarkers after stroke are limited (2). Hence, a crucial first step to increase knowledge on biomarkers of stroke recovery is to gain a better understanding of the time course of both stroke recovery and biomarker patterns. Biomarkers can later be used for outcome predictions after stroke.

Detailed description

BACKGROUND Stroke survivors frequently suffer disabilities including motor and cognitive problems, impairments in speech and vision, depression, and several other disabilities that worsen their quality of life. Some will recover fully after stroke and others will have permanent impairements. Few studies show trajectories of recovery in different domains after stroke, hence recovery time-lines are not fully known. Also, the whole range of mechanisms leading to recovery are not precisely known (1). To monitor those mechanisms one can utilize biomarkers. In parallel to the studies of recovery, studies on time series of biomarkers after stroke are limited (2). Hence, a crucial first step to increase knowledge on biomarkers of stroke recovery is to gain a better understanding of the time course of both stroke recovery and biomarker patterns. Biomarkers can later be used for outcome predictions after stroke. WORK PLAN AIM Determine temporal profiles describing the speed, order, and degree of recovery in neurological and cognitive functions in various domains with simultaneous profiling of changes in blood biomarker concentrations, in the acute, subacute phases and long-term of stroke. Determine individual and interindividual variations in recovery in the different domains. Informed consent Written informed consent will be obtained from all willing participants or their next-of-kin.

Interventions

OTHERObservational - all

All stroke patients are included.

Sponsors

Göteborg University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Investigators enrol patients presenting with first-ever ischemic stroke or intracerebral haemorrhage admitted to the stroke units at the Sahlgrenska University Hospital in Gothenburg, Sweden. The inclusion criteria are: • first-ever acute ischemic stroke; or intracerebral hemorrhage. The

Exclusion criteria

are: * pre-stroke mRS score of ≥3; * severe neurodegenerative disease, cerebral neoplasm or terminal illness; and * patients considered unlikely to be able to participate in or to understand and/or comply with study procedures during follow-up visits at the hospital.

Design outcomes

Primary

MeasureTime frameDescription
Medical data Clinical dataBaseline, and change from baseline at 3, 6 and 12 months; 2 and 5 years.Stroke subtype, medical history, life style questions between baseline and follow-ups
Stroke severityBaseline, and change from baseline at 3, 6 and 12 months; 2 and 5 years.Change of National Institutes of Health Stroke Scale (NIHSS) between baseline and follow-ups.
Functional independencePre-stroke estimation, baseline, and change from baseline at 3, 6 and 12 months; 2 and 5 years.Change of modified Ranking Scale (mRS) functional independence
Walking abilityBaseline, and change from baseline at 3, 6 and 12 months; 2 and 5 years.Change in functional Ambulation Category between baseline and follow ups.
Postural controlBaseline, and change from baseline at 3, 6 and 12 months; 2 and 5 years.Change in postural control, evaluated by Berg Balance Scale (BBS), between baseline and follow ups.
Blood samplesBaseline, and change from baseline at 3, 6 and 12 months; 2 and 5 yearsAnalyses of plasma protein levels and circulating RNA profiles in comparison to baseline
FMA-arm testBaseline, and change from baseline at 3, 6 and 12 months; 2 and 5 yearsChange in performance on Fugl-Meyer Assessment of Motor Recovery after Stroke test between baseline and follow-up.
SAFEBaseline, and change from baseline at 3, 6 and 12 months; 2 and 5 yearsChange in performance on Shoulder Abduction and Finger Extension (SAFE) score between baseline and follow ups.
MoCABaseline, and change from baseline at 3, 6 and 12 months; 2 and 5 yearsChange in the Montreal Cognitive Assessment between baseline and follow ups.
NeuroimagingBaseline, and change from baseline at 3, and 12 months; 2 yearsChanges in MRI scans between baseline and follow-ups.
D-FISBaseline, and change from baseline at 3, 6 and 12 months; 2 and 5 yearsChange in the Daily Fatigue Impact Scale (D-FIS) between baseline and follow ups.
HADBaseline, and change from baseline at 3, 6 and 12 months; 2 and 5 yearsChange in the Hospital Anxiety and Depression (HAD) scale between baseline and follow ups.
SISBaseline, and change from baseline and 3, 6 and 12 months; 2 and 5 yearsChange in domains of Stroke Impact Scale (SIS) between baseline and follow ups.
FASBaseline, and change from baseline at 3, 6 and 12 months; 2 and 5 yearsChange in the Verbal Fluency Test between baseline and follow ups.
CWTBaseline, and change from baseline at 3, 6 and 12 months; 2 and 5 yearsChange in the Color-Word Interference test between baseline and follow ups.
TMTBaseline, and change from baseline at 3, 6 and 12 months; 2 and 5 yearsChange in the Trail Making Test between baseline and follow ups.
RBANSBaseline, and change from baseline at 3, 6 and 12 months; 2 and 5 yearsChange in the 10-word test from Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) between baseline and follow ups.

Countries

Sweden

Contacts

Primary ContactChristina Jern, MD, PhD
christina.jern@neuro.gu.se+46-31-3435720
Backup ContactJood Katarina, MD, PhD
katarina.jood@neuro.gu.se+46-31-342 90 52

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026